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Abstract
Background: Pompe disease is an autosomal recessive disorder caused by deficiency of the lysosomal α–1,4-
glucosidase leading to accumulation of glycogen in target tissues with progressive organ failure. While the early
infantile-onset form is characterized by early severe hypertrophic cardiomyopathy with cardiac and respiratory
failure, clinically relevant cardiomyopathy seems to be uncommon in patients with late-onset Pompe disease, and
the prevalence and nature of myocardial abnormalities are still to be clarified.
Methods: Seventeen patients with genetically proven late-onset Pompe disease (50 ± 18 years, 11 male) and
18 age- and gender-matched healthy controls (44 ± 10 year, 12 male) underwent comprehensive cardiovascular
magnetic resonance (CMR) including conventional and advanced techniques: cine and feature tracking-based
strain imaging for depiction of (even subtle) systolic LV dysfunction as well as late gadolinium enhancement
(LGE) and myocardial extracellular volume fraction (ECV) quantification for focal and diffuse fibrosis detection.
Results: All patients had normal left ventricular (LV) and right ventricular (RV) volumes and normal LV and RV
ejection fraction. In comparison to healthy controls, neither conventional cine nor advanced feature-tracking
based-strain imaging could depict any (subclinical) myocardial systolic dysfunction. Three (18%) of the patients
had non-ischemic LGE in the basal inferolateral wall and 21% demonstrated elevated global ECV values suggestive
of interstitial myocardial fibrosis. Non-specific abnormalities such as left atrial (LA) dilatation were present in two
patients, while LV hypertrophy was seen only in one. Two of the three LGE-positive patients were also hypertensive
and demonstrated high global ECV values (>30%) in addition to dilated LA. After a median follow-up of 25 (11–29)
months, only one cardiovascular event occurred: one of the LGE-positive patients with a high cardiovascular risk
profile suffered an acute coronary syndrome.
Conclusion: In contrast to the early infantile-onset form of Pompe disease, mild and rather non-specific cardiac
abnormalities can be detected by CMR only in a small proportion of patients with late-onset Pompe disease. The
observed structural abnormalities seem to result from an interplay between the storage disease and other
comorbidities and they did not affect short-term to mid-term prognosis in adult Pompe patients.
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Background
Glycogen storage disease type II or Pompe disease is an
autosomal recessive disorder caused by deficiency of the
lysosomal enzyme α–1,4-glucosidase (GAA) leading to
accumulation of glycogen resulting in lysosomal dysfunc-
tion, autophagy, and progressive tissue damage [1, 2].
Severity varies by age of onset, rate of progression and ex-
tent of organ involvement comprising primarily the skel-
etal and respiratory muscles, but also the human heart [1].
In the early infantile-onset form of Pompe disease, severe
(obstructive) cardiomyopathy with cardiac and respiratory
failure along with progressive quadriplegia is present very
early, and survival without enzyme replacement therapy
(ERT) beyond one year is extremely rare [3]. The term
late-onset Pompe disease (LOPD) sums up subtypes with
late-infantile, childhood, juvenile, or adult onset of disease.
Patients with LOPD suffer from a progressive myopathy
of the limb-girdle and trunk muscles, and the diaphragm
[4]. While clinically relevant cardiomyopathy is uncom-
mon the prevalence and nature of myocardial abnormal-
ities are still to be clarified [5–8].
Cardiovascular magnetic resonance (CMR) is a highly
sensitive tool for detection of functional and structural
myocardial abnormalities in both ischemic and non-
ischemic cardiomyopathies [9]. In addition to depiction
of focal myocardial damage and/or fibrosis by conven-
tional late gadolinium enhancement (LGE), advanced
equilibrium contrast CMR techniques for quantifica-
tion of myocardial extracellular volume fraction (ECV)
have been developed and validated for quantification of
myocardial interstitial fibrosis [10]. Moreover, feature-
tracking CMR using the standard cine images acquired
in routine protocols is a novel technique that allows
quantification of strain to detect even subtle changes in
LV function and has been successfully validated against
myocardial tagging [11].
The aim of the present study was to look for even
subclinical myocardial involvement by means of com-
prehensive CMR, including conventional and advanced
techniques, in a population of patients with LOPD and
no previous history of cardiac disease.
Methods
Study population
Seventeen patients with known LOPD (50 ± 18 years, 11
male) were prospectively enrolled between July 2013 and
March 2016. Diagnosis was genetically confirmed in all
patients by detection of two pathogenic mutations of the
GAA gene. All patients underwent detailed cardiac and
neurologic evaluation including comprehensive CMR
studies. In patients receiving home ventilatory support
due to severe respiratory muscle weakness, CMR was
performed using non-invasive ventilation (NIV) during
the procedure. Exclusion criteria were inability to lie
flat and perform the required breathholds as well as con-
traindications to CMR or to gadolinium contrast adminis-
tration. Additionally, 18 age- and gender-matched healthy
subjects (44 ± 10 year, 12 male) were included and repre-
sented the control group. All patients were periodically
followed up in three months intervals. Any cardiovascular
event, including heart failure, acute coronary syndromes,
detection of arrhythmia, any cardiac hospitalization and
cardiac death, was documented.
CMR
ECG-gated CMR studies were performed on 1.5 T
scanners (Aera, Siemens Medical Solutions, Erlangen,
Germany and Achieva, Philips, Best, The Netherlands)
using commercially available cardiac software, electro-
cardiographic triggering, and cardiac-dedicated surface
coils. Cine-imaging was performed using a steady-state-
free-precession (SSFP) sequence in three long-axis slices
(four-, three and two-chamber) and a stack of short-axis
slices completely covering the LV. LGE imaging was per-
formed using a T1-weighted inversion recovery gradient-
echo sequence 10–15 min after intravenous contrast
administration (0.10 mmol/kg Magnevist®) in the same
imaging planes as the cine-images. For ECV imaging, T1
measurements were made using a Modified Look-
Locker inversion recovery (MOLLI) sequence before
and 15–20 min after intravenous contrast (following
LGE-imaging) as described elsewhere [12].
CMR analysis
CMR analysis was performed off-line by two experi-
enced readers. Ventricular volumes, ejection fraction
and LV mass were derived by contouring endo- and
epicardial borders on the short-axis cine images and
indexed to body surface area. The papillary muscles
were included in the LV cavity. LV hypertrophy was
considered present whenever maximal end-diastolic
wall thickness was ≥ 13 mm in men and ≥ 12 mm in
women. The ratio of LV mass to end-diastolic volume
was used as an index of concentric hypertrophy [13].
Left atrial (LA) surface was measured at end-systole in 4-
chamber view and when ≥ 29 cm2 in men and ≥ 27 cm2 in
women defined as LA dilatation [14]. LGE presence and
pattern were visually assessed on the short-and long-axis
images by using the AHA 17-segment model. LGE pattern
was globally assessed as: ischemic (subendocardial and/
or transmural) and non-ischemic (subepicardial and/or
intramural) [15].
ECV measurement
For myocardial ECV calculation, motion corrected pre-
and post-contrast T1 pixel maps, automatically generated
by the scanner after each MOLLI acquisition, were used
for processing with Image J (http://rsbweb.nih.gov/ij/)
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software as previously described [12, 16]. R1 maps were
generated by taking the reciprocal of the each T1
map on a pixel-by-pixel basis and ΔR1 maps were
computed by subtracting the pre-contrast R1 map
from the post-contrast R1 map. For each patient/
healthy subject one mid-ventricular short-axis slice served
for analysis. Average pixel signal intensity (ΔR1 value) was
measured in the chosen short-axis ΔR1 map using two
manually delineated regions of interest, one in the septum
and one in the lateral wall. Additionally, a region of
interest was placed in the blood pool, carefully avoiding
papillary muscles and LV trabeculations. The following
formula was used for myocardial ECV computation:
Extracellular volume fraction (ECV) = λ x (1- hematocrit),
where the partition coefficient λ =ΔR1 (myocardium)/
ΔR1(blood) (Ref). Global myocardial ECV was obtained
by averaging septal and lateral wall ECV values in each
patient/control.
Feature tracking analysis
The feature tracking analysis was performed on the
standard acquired cine CMR images using dedicated
software (CVI42, Circle Imaging, Leiden, Netherlands).
Firstly, landmarks for LV base (at the mitral valve ring)
and apex were defined in all three long-axis slices at
end-diastole. Following, endocardial and epicardial bor-
ders were manually delineated in the end-diastolic
frame in the three long-axis slices and in the short-axis
stack, from the most basal slice without trough plane
distortion from the LV outflow tract to the most apical
one. Both the landmarks and contours were automatic-
ally propagated through the cardiac cycle and manually
corrected in case of inaccuracies. Global peak systolic
longitudinal strain (GLS) was derived from the long-
axis cines, while short-axis cines were used to derive
global peak circumferential (GCS) and radial strains
(GRS) [11].
Statistical analysis
Continuous variables with normal distribution are
expressed as mean and standard deviation (SD). Skewed
variables were expressed as median and interquartile
range (IQR). Categorical variables are expressed as fre-
quency with percentage. t-Student test was used for
comparison of normally distributed characteristics be-
tween patients and controls. Levene’s test was used for
testing equality of variances. The chi-square test with
Yate’s correction was used to compare non-continuous
variables expressed as proportions. Statistical analysis
was performed using SPSS software for Windows (version
19.0, IBM Corp., Armonk, NY). A p-value ≤ 0.05 was con-
sidered statistically significant.
Results
General characteristics of the study population
General characteristics of patients and healthy controls
are shown in Table 1. Seventeen patients with LOPD
(juvenile vs. adult disease onset: 24 vs. 76%) had a mean
age of 50 ± 18 years (median and IQR: 30 year; 20–
43 years) and 65% were male (n = 11). Six patients with
LOPD (35%) had known hypercholesterolemia, signifi-
cantly more frequent compared to controls. Addition-
ally, three patients (18%) had arterial hypertension, all
under pharmacological treatment, and two patients had
diabetes in comparison to none of the controls. None
of the patients with LOPD had known cardiac disease
at study inclusion.
Characteristics related to pompe disease
As illustrated in Table 2, patients with LOPD specified
an average disease duration of 19 ± 14 years (median and
IQR: 17 years; 8–29 years) with a median age at diagno-
sis of 30 year (20–43 years). 16 out of 17 patients
showed proximal and symmetrical limb-girdle weakness
(Fig. 1a). Gait abnormalities were present in all of these
patients, and constant use of walking aids was necessary
in three individuals. Mean walking distance in the 6 min
walk test was 398.4 ± 156.5 m with a range between 164
and 610 m (n = 14). Upright forced vital capacity (FVC)
as measured using a handheld electronic spirometer was
reduced to 62.0% ± 29.2% from the predicted value. Five
patients (29%) showed normal FVC, and eight individ-
uals (47%) already received nighttime NIV prior to en-
rollment. Twelve patients (71%) had been receiving ERT
in a standard dosage (alglucosidase alfa, 20 mg/kg body
weight every two weeks) for 72 months on average (29–83
months).
CMR results, conventional parameters
Data related to CMR examinations are shown in Table 3.
Both patients and controls had left and right ventricular
(LV/RV) dimension, including LV mass, and ejection
Table 1 General characteristics of the patients and controls
Pompe Controls P-Value
N = 17 N = 18
Age, years 50 ± 18 44 ± 10 0.24
Male, n (%) 11 (65) 12 (67) 1.00
BMI, kg/m2 24 ± 4 24 ± 3 0.95
Hypertension, n (%) 3 (18) 0 (0) 0.10
Diabetes, n (%) 2 (12) 0 (0) 0.23
Hypercholesterolemia, n (%) 6 (35) 0 (0) 0.008
Obesity, n (%) 3 (18) 2 (11) 0.66
Cardiac symptoms, n (%) 0 (0) 0 (0) 1.00
BMI body mass index
Bold indicates p < 0.05.
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fraction within the normal range without any significant
difference between both groups. Only one patient
showed mild septal hypertrophy compared to none of
the controls. Eighteen percent (n = 3) of the patients
showed LA dilatation compared to none of the controls
(p = NS). Moreover, three patients (18%) with adult onset
of disease, had LGE with a non-ischemic pattern, located
mid-wall in the basal inferolateral segment (Figs. 1b-c
and 2). Two of these three patients had a history of
hypertension associated with LA dilatation as well as
elevated cholesterol levels and an increased body weight.
Interestingly, the same two (male) patients showed bor-
derline septal thickness (12 mm). In the third (female)
LGE-positive patient, we did not find any other patho-
logical CMR finding. Interestingly, this patient was obese
(BMI 30.4) and reported a very long disease duration of
34 years from the occurrence of initial symptoms.
CMR results-advanced imaging parameters: feature-tracking
derived strain
Regarding functional (myocardial deformation) parame-
ters (Table 3), there was no significant difference between
feature-tracking derived GLS in patients and controls
(−19 ± 2.5% vs. −19.1 ± 2.2%, p =NS). Some minor differ-
ences were measured in the Pompe group in compari-
son to the control group regarding GCS (−20.1 ± 2.5%
vs. –18.6 ± 2.2%, p = 0.011) and GRS (41.3 ± 8.2% vs.
34.5 ± 6.9%, p = 0.012). Moreover, within the Pompe
group both GCS and GRS were relatively higher in
hypertensive compared to normotensive patients
(−23.9 ± 1.4% vs. –20.2 ± 2.3%, p = 0.017 and 52.0 ± 5.4%
vs. 39.0 ± 7.1%, p = 0.028). However, all obtained global
strain values were within normal range in both groups.
Table 2 Pompe disease related patient characteristics
Pompe
N = 17
Age at diagnosis, years 31 ± 14
Disease duration, years 19 ± 14
Hypoventilation, n (%) 9 (53)
Mechanical ventilatory support, n (%) 8 (47)
Severely impaired FVC*, n (%) 7 (44)
Limb girdle weakness, n (%) 16 (94)
Walking aid necessary, n (%) 3 (18)
Six minute walk test, m 410 (234–512)
Enzyme replacement therapy, n (%) 12 (71)
Duration of enzyme therapy, months 72 (29–83)
* - <50% of the predicted value; FVC-upright forced vital capacity
Fig. 1 a Transverse T1-weighted spin-echo CMR of the thigh musculature in a patient with late-onset Pompe disease (LOPD). The adductor and
ischiocrural muscles show symmetrical and confluent hyperintensity indicative of severe fibrosis and lipodystrophy (red stars). Some patchy fatty
replacement can also be seen in the vastus lateralis muscles (yellow arrows) and, to a much lesser extent, in the vastus medialis muscles (blue arrows).
b–c Short and long-axis late gadolinium enhancement (LGE) CMR images of the same patient showing no myocardial involvement (no fibrosis, no
fatty replacement)
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CMR results-advanced imaging parameters: ECV
measurement
There was no significant difference in global ECV
between Pompe patients (n = 14) and controls (n = 16) in
whom successful pre- and post-contrast T1-mapping
was achieved (27.3 ± 4.5% vs. 25.4 ± 2.5%, p =NS). The
non-significant differences were unchanged when look-
ing at septal and lateral wall (LW) ECV values. Increased
global ECV values (>30%) were found in three (21%) of
the Pompe patients - but in none of the controls.
Among these three, two were also LGE-positive. How-
ever, the increase in ECV involved equally the septum
and mid-ventricular LV lateral wall, in areas where no
LGE could be visually depicted.
Follow-up for cardiovascular events
Patients were clinically followed up for occurrence of
cardiovascular events for a median of 25 months (11–29
months). During this follow-up period, one LGE-positive
patient with a high cardiovascular risk profile (diabetes,
hypertension, high cholesterol) experienced an acute
coronary syndrome with subsequent diagnosis of two-
vessel coronary artery disease, 23 months after inclusion
to the study. No other cardiovascular events were regis-
tered in the above time interval.
Discussion
To the best of our knowledge, this is the first study
aiming to detect even subclinical myocardial involve-
ment by means of comprehensive CMR, including con-
ventional and advanced techniques — in a population
of adult patients with LOPD and no previous history of
cardiac disease. The major findings of this study can be
summarized as follows and are in contrast to previous
findings in early infantile-onset Pompe disease [3]: (i)
neither conventional (cine) nor advanced (feature-
tracking based strain) imaging could depict subclinical
myocardial systolic dysfunction; (ii) some Pompe pa-
tients demonstrated presence of non-ischemic LGE in
the basal LV inferolateral wall and showed elevated
ECV suggestive of myocardial interstitial fibrosis; (iii)
non-specific abnormalities such as LA dilatation were
present in a few Pompe patients, while LV hypertrophy
was seen only in one.
A study using state-of-the-art CMR of functional and/or
structural myocardial abnormalities in LOPD was neces-
sary since previous studies (mostly using echocardiography
and a small sample size) showed rather heterogeneous and
Table 3 CMR parameters in the study and control groups
Pompe Controls P-Value
N = 17 N = 18
Heart rate, bpm 69 ± 10 64 ± 12 0.14
BSA, kg/m2 0.9 ± 0.2 0.9 ± 0.2 0.90
LV-EDV index, ml/m2 75 ± 12 75 ± 15 0.85
LV-ESV index, ml/m2 28 ± 7 30 ± 7 0.40
LV-EF, % 62 ± 6 61 ± 4 0.40
LV mass index, g/m2 48 ± 8 53 ± 14 0.17
LV hypertrophy, n (%) 1 (6) 0 (0) 0.49
LV mass/volume ratio 0.65 ± 0.10 0.71 ± 0.13 0.14
RV-EDV index, ml/m2 74 ± 14 77 ± 14 0.54
RV-ESV index, ml/m2 30 ± 9 32 ± 10 0.42
RV-EF, % 60 ± 7 60 ± 9 0.73
LV-GLS, % −19 ± 2.5 −19.1 ± 2.2 0.93
LV-GRS, % 41.3 ± 8.2 34.4 ± 6.9 0.012
LV-GCS, % −20.8 ± 2.5 −18.7 ± 2.4 0.015
LA dilatation, n (%) 3 (18) 0 (0) 0.10
LGE, n (%) 3 (18) 0 (0) 0.10
Global ECV, %* 27.3 ± 4.5 25.4 ± 2.5 0.18
Septal ECV, %* 28.4 ± 4.9 25.9 ± 2.8 0.12
LW ECV, %* 26.2 ± 4.2 24.9 ± 2.5 0.33
LV left ventricle, EDV end-diastolic, ESV end-systolic, EF ejection fraction, GLS
global longitudinal strain, GRS global radial strain, GCS global circumferential
strain, LA left atrium, LGE late gadolinium enhancement, ECV extracellular
volume fraction, LW lateral wall
*ECV measurement was performed in N = 14 Pompe patients and
N = 16 controls
Bold indicates p < 0.05.
Fig. 2 CMR of a patient with late-onset Pompe disease (LOPD) showing non-ischemic (intramural) late gadolinium enhancement (LGE) in the
basal left ventricular inferolateral wall segments (red arrows) in short- (a) and long-axis views (b)
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inconsistent results [5–8]. In these earlier reports, only a
minority of adult Pompe patients demonstrated LV hyper-
trophy (always mild), whereas a small number showed mild
degrees of systolic/diastolic dysfunction [5–7]. Interest-
ingly, a more recent study found no echocardiographic ab-
normalities, including advanced 2D strain imaging, in 12
patients with LOPD [8]. Moreover, CMR was performed in
a subgroup of their patients and no myocardial LGE was
detected [8]. Unfortunately, how many patients underwent
CMR and cardiovascular comorbidities are not reported.
In our present study, non-ischemic LGE was present
in a small proportion of patients and its cause is debat-
able. A similar intramural LGE-pattern in the basal LV
inferolateral wall has already been described in patients
with impaired cellular energy metabolism due to gen-
etic mitochondrial myopathy and seems to be at least
partially related to a regional increase in LV wall stress
[17]. However, even though mild accumulation of
glycogen seems to be present also in cardiomyocytes,
histopathological studies failed to depict myocardial cell
death or fibrosis in LOPD [18]. On the other hand,
both non-ischemic LGE and ECV increase have been
described in association with hypertensive heart disease
[19]. In this context, it needs to be emphasized that
two of the three LGE-positive patients in the current
study were hypertensive and showed a high global ECV
value in the presence of a dilated LA. Yet, in contrast
to our present results, ECV increase in hypertensive pa-
tients appears to be related to an increase in LV mass
and a decrease in circumferential deformation parame-
ters [19]. Thus, a clear delineation between the impact
of glycogen storage and any comorbidity potentially caus-
ing focal or diffuse fibrosis may be impossible in patients
with LOPD. Additionally, the minor differences in radial
and circumferential deformation between Pompe and con-
trol groups can be explained by different load conditions
since GCS and GRS were reported to differ significantly
from controls exclusively in hypertensive patients with an-
tihypertensive medication [20]. Finally, compared to the
aforementioned study by Morris et al., our patients were
older (mean age 50 year vs. 38 years), more frequently
male (65% vs. 50%) and some had already comorbidities
like hypertension or diabetes [8]. These factors per se
might explain the occurrence of LA dilatation, suggesting
impaired LV filling in the hypertensive individuals at least.
Taken together, in a small proportion of patients with
LOPD mild and non-specific cardiac abnormalities can be
detected by CMR and they possibly result from an inter-
play between glycogen storage and concomitant disease.
No clear impact of the findings on short-term to mid-
term prognosis was found. However, their long-term
consequences remain uncertain and yet to be clarified.
Nevertheless, even mild cardiac involvement is only rarely
observed in patients with LOPD and does not seem to be
of any prognostic value. Therefore, comprehensive CMR
studies are not routinely required in these patients from a
clinical point-of-view. Obviously, there are no sufficient
and specific data to suggest any evidence-based recom-
mendations for cardiac monitoring in LOPD patients. Pre-
vious reports addressing e.g. metabolic conditions or rare
neuromuscular disorders suggested cardiac evaluations
comprising ECG and echocardiography at diagnosis and
thereafter at least every 5 years in the case of normal
findings. Based on the results of this study, we would
recommend a baseline cardiac assessment, including clin-
ical history, physical examination, a 12-lead ECG and
echocardiography at diagnosis. In case of normal findings,
additional CMR is not required and repeated cardiac eval-
uations can be performed every 4–5 years. However, in
case of abnormal cardiac findings using conventional
methods, additional CMR may be scheduled in order to
better characterize and assess the nature and clinical value
of the respective findings since LOPD patients may also
suffer from other (ischemic as well as non-ischemic)
diseases.
Obviously, the sample size was still small in this
study. However, Pompe disease is a rare condition and
CMR may be challenging and sometimes impossible in
patients with advanced respiratory muscle weakness.
Taking this into account, the present study group of 17
patients with comprehensive CMR is noteworthy. Our
control group consisted of age- and gender-matched
healthy controls, while some of the Pompe patients had
comorbidities potentially causing structural myocardial al-
terations. In addition, chronic respiratory muscle weak-
ness itself may have a structural impact on the heart in
affected patients. Echocardiography was not systematically
performed at the time of CMR, so comprehensive data on
diastolic function were not available. However, it is well
known that the diagnosis of diastolic dysfunction by echo-
cardiography has limited reliability, particularly in the ini-
tial stages of diastolic dysfunction [21]. Finally, a large
proportion of our patients were receiving ERT which
may reduce or mask any sequelae of glycogen accumu-
lation in the myocardial tissue. Given the fact that ERT
for Pompe disease is widely available in industrialized
countries, we consider it unlikely that larger numbers
of untreated patients will undergo CMR in the future.
However, existing echocardiography-based data support
that ERT has no significant impact on cardiac parameters
in LOPD [6, 7].
Conclusions
In contrast to the early infantile-onset form of Pompe
disease, mild and rather non-specific cardiac abnormal-
ities can be detected by CMR only in a small propor-
tion of patients with late-onset Pompe disease. The
observed structural abnormalities seem to result from
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an interplay between the storage disease and other co-
morbidities and they did not affect short-term to mid-
term prognosis in patients with LOPD.
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